Cardioprotective potential of protocatechuic acid against doxorubicin-induced cardiotoxicity in rats

Leila Safaeian , Zahra Haghighatian, Mohammadreza Zamani

Abstract


Background and purpose: Chemotherapy with doxorubicin (DOX) is associated with toxicity in many organs including cardiac tissue. A large body of evidence has suggested that phenolic acids, such as protocatechuic acid (PCA), have beneficial effects on cardiovascular problems. This investigation was conducted to evaluate the ameliorative properties of PCA against DOX-induced cardiotoxicity in Wistar rats.

Experimental approach: Animals were treated with PCA (50, 100, and 200 mg/kg, orally) for 10 days. On the 7th day, a single injection of DOX (20 mg/kg/day, i.p.) was administered to induce cardiotoxicity. Electrocardiography, biochemical analysis of cardiac markers, and histological inspections were performed.

Findings/Results: Pretreatment with PCA, especially at the doses of 100 and 200 mg/kg for 7 days before the administration of DOX, significantly improved cardiac rhythm and pathological changes, reduced serum levels of creatine phosphokinase-MB, lactate dehydrogenase, aspartate aminotransferase, lipid peroxides and also prevented heart weight rise.

Conclusions and implications: The in-vivo findings of the current study revealed that PCA exhibits protective effects against DOX-induced cardiotoxicity. These results suggest that PCA, a natural phenolic acid, may serve as a promising candidate for cardioprotective interventions in clinical trials involving chemotherapy with DOX. 

 

 


Keywords


Cardiotoxicity; Doxorubicin; Protocatechuic acid; Rat.

Full Text:

PDF

References


Schimmel KJ, Richel DJ, Van den Brink RB, Guchelaar HJ. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev. 2004;30(2):181-191.DOI: 10.1016/j.ctrv.2003.07.003.

Mostafa RE, Morsi AH, Asaad GF. Anti-inflammatory effects of saxagliptin and vildagliptin against doxorubicin-induced nephrotoxicity in rats: attenuation of NLRP3 inflammasome up-regulation and tubulo-interstitial injury. Res Pharm Sci. 2021;16(5):547-458.DOI: 10.4103/1735-5362.323920.

Sheibani M, Azizi Y, Shayan M, Nezamoleslami S, Eslami F, Farjoo MH, et al. Doxorubicin-induced cardiotoxicity: an overview on pre-clinical therapeutic approaches. Cardiovasc Toxicol. 2022;22(4):292-310.DOI: 10.1007/s12012-022-09721-1.

Zhao L, Zhang B. Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. Sci Rep. 2017;7(1):44735,1-11.DOI: 10.1038/srep44735.

Xinyong C, Zhiyi Z, Lang H, Peng Y, Xiaocheng W, Ping Z, et al. The role of toll-like receptors in myocardial toxicity induced by doxorubicin. Immunol Lett. 2020;217:56-64.DOI: 10.1016/j.imlet.2019.11.001.

Avagimyan A, Sheibani M, Pogosova N, Mkrtchyan L, Yeranosyan H, Aznauryan A, et al. Possibilities of dapagliflozin-induced cardioprotection on doxorubicin+cyclophosphamide mode of chemotherapy-induced cardiomyopathy. Int J Cardiol. 2023;391:131331.DOI: 10.1016/j.ijcard.2023.131331.

Zhang S, Gai Z, Gui T, Chen J, Chen Q, Li Y. Antioxidant effects of protocatechuic acid and protocatechuic aldehyde: old wine in a new bottle. Evid Based Complement Alternat Med. 2021;2021:6139308,1-19.DOI: 10.1155/2021/6139308.

Masella R, Santangelo C, D'Archivio M, LiVolti G, Giovannini C, Galvano F. Protocatechuic acid and human disease prevention: biological activities and molecular mechanisms. Curr Med Chem. 2012;19(18):2901-2917.DOI: 10.2174/092986712800672102.

Khan AK, Rashid R, Fatima N, Mahmood S, Mir S, Khan S, et al. Pharmacological activities of protocatechuic acid. Acta Pol Pharm. 2015;72(4):643-650.‏PMID: 26647619.

Deng JS, Lee SD, Kuo WW, Fan MJ, Lin YM, Hu WS, et al. Anti-apoptotic and pro-survival effect of protocatechuic acid on hypertensive hearts. Chem Biol Interact. 2014;209:77-84.DOI: 10.1016/j.cbi.2013.11.017.

Tang XL, Liu JX, Dong W, Li P, Li L, Lin CR, et al. The cardioprotective effect of protocatechuic acid on myocardial ischemia/reperfusion injury. J Pharmacol Sci. 2014;125(2):176-183.DOI: 10.1254/jphs.13247fp.

Wang D, Wei X, Yan X, Jin T, Ling W. Protocatechuic acid, a metabolite of anthocyanins, inhibits monocyte adhesion and reduces atherosclerosis in apolipoprotein E-deficient mice. J Agric Food Chem. 2010;58(24):12722-12728.DOI: 10.1021/jf103427j.

Bhattacharjee N, Dua TK, Khanra R, Joardar S, Nandy A, Saha A, et al. Protocatechuic acid, a phenolic from Sansevieria roxburghiana leaves, suppresses diabetic cardiomyopathy via stimulating glucose metabolism, ameliorating oxidative stress, and inhibiting inflammation. Front Pharmacol. 2017;8:251.DOI: 10.3389/fphar.2017.00251.

Ciftci O, Disli OM, Timurkaan N. Protective effects of protocatechuic acid on TCDD-induced oxidative and histopathological damage in the heart tissue of rats. Toxicol Ind Health. 2013;29(9):806-811.DOI: 10.1177/0748233712442735.

Shafiee F, Safaeian L, Gorbani F. Protective effects of protocatechuic acid against doxorubicin- and arsenic trioxide-induced toxicity in cardiomyocytes. Res Pharm Sci. 2023;18(2):149-158.DOI: 10.4103/1735-5362.367794.

Ye P, Li WL, Bao LT, Ke W. Mulberrin confers protection against doxorubicin-induced cardiotoxicity via regulating AKT signaling pathways in mice. Oxid Med Cell Longev. 2022; 2022:2967142,1-18.DOI: 10.1155/2022/2967142.

Satyam SM, Bairy LK, Shetty P, Sainath P, Bharati S, Ahmed AZ, et al. Metformin and dapagliflozin attenuate doxorubicin-induced acute cardiotoxicity in Wistar rats: an electrocardiographic, biochemical, and histopathological approach. Cardiovasc Toxicol. 2023;23(2):107-119.DOI: 10.1007/s12012-023-09784-8.

Krzysztoforska K, Piechal A, Wojnar E, Blecharz-Klin K, Pyrzanowska J, Joniec-Maciejak I, et al. Protocatechuic acid prevents some of the memory-related behavioural and neurotransmitter changes in a pyrithiamine-induced thiamine deficiency model of Wernicke–Korsakoff syndrome in rats. Nutrients. 2023;15(3):625,1-25.DOI: 10.3390/nu15030625.

Thakare VN, Patil RR, Suralkar AA, Dhakane VD, Patel BM. Protocatechuic acid attenuate depressive-like behavior in olfactory bulbectomized rat model: behavioral and neurobiochemical investigations. Metab Brain Dis. 2019;34(3):775-787.DOI: 10.1007/s11011-019-00401-8.

Zhao L, Tao X, Qi Y, Xu L, Yin L, Peng J. Protective effect of dioscin against doxorubicin-induced cardiotoxicity via adjusting microRNA-140-5p-mediated myocardial oxidative stress. Redox Biol. 2018;16:189-198.DOI: 10.1016/j.redox.2018.02.026.

Safaeian L, Mirian M, Bahrizadeh S. Evolocumab, a PCSK9 inhibitor, protects human endothelial cells against H2O2-induced oxidative stress. Arch Physiol Biochem. 2022;128(6):1681-1686.DOI: 10.1080/13813455.2020.1788605.

Lee SH, Choi BY, Kho AR, Jeong JH, Hong DK, Lee SH, et al. Protective effects of protocatechuic acid on seizure-induced neuronal death. Int J Mol Sci. 2018;19(1):187,1-12.DOI: 10.3390/ijms19010187.

Habib SA, Suddek GM, Rahim MA, Abdelrahman RS. The protective effect of protocatechuic acid on hepatotoxicity induced by cisplatin in mice. Life Sci. 2021;277:119485,1-11.DOI: 10.1016/j.lfs.2021.119485.

Owumi SE, Ajijola IJ, Agbeti OM. Hepatorenal protective effects of protocatechuic acid in rats administered with anticancer drug methotrexate. Hum Exp Toxicol. 2019;38(11):1254-1265.DOI: 10.1177/0960327119871095.

Chook CY, Cheung YM, Ma KY, Leung FP, Zhu H, Niu QJ, et al. Physiological concentration of protocatechuic acid directly protects vascular endothelial function against inflammation in diabetes through Akt/eNOS pathway. Front Nutr. 2023;10:1060226,1-11.DOI: 10.3389/fnut.2023.1060226.

Sangweni NF, Gabuza K, Huisamen B, Mabasa L, van Vuuren D, Johnson R. Molecular insights into the pathophysiology of doxorubicin-induced cardiotoxicity: a graphical representation. Arch Toxicol. 2022;96(6):1541-1550.DOI: 10.1007/s00204-022-03262-w.

Tavakoli Dargani Z, Singla DK. Embryonic stem cell-derived exosomes inhibit doxorubicin-induced TLR4-NLRP3-mediated cell death-pyroptosis. Am J Physiol Heart Circ Physiol. 2019;317(2):H460-H471.DOI: 10.1152/ajpheart.00056.2019.

Durdagi G, Pehlivan DY, Oyar EO, Bahceci SA, Ozbek M. Effects of melatonin and adrenomedullin in reducing the cardiotoxic effects of doxorubicin in rats. Cardiovasc Toxicol. 2021;21(5):354-364.DOI:10.1007/s12012-020-09625-y.

Ammar ESM, Said SA, Suddek GM, El-Damarawy SL. Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats. Can J Physiol Pharmacol. 2011;89(4):269-276.DOI: 10.1139/y11-020.

Xie Z, Wu W, Xing H, Cai Y, Wang X, Chen J. Bradycardia associated with pegylated liposomal doxorubicin administration: a case report. Eur J Hosp Pharm. 2017;24(2):128-130.DOI: 10.1136/ejhpharm-2015-000817.

Roussel J, Champeroux P, Roy J, Richard S, Fauconnier J, Le Guennec JY, et al. The complex QT/RR relationship in mice. Sci Rep. 2016;6(1):25388,1-9.DOI: 10.1038/srep25388.

Mulla W, Murninkas M, Levi O, Etzion Y. Incorrectly corrected? QT interval analysis in rats and mice. Front Physiol. 2022;13:1002203,1-8.DOI: 10.3389/fphys.2022.1002203.

Arunachalam S, Kim SY, Kim MS, Yi HK, Yun BS, Lee DY, et al. Adriamycin inhibits adipogenesis through the modulation of PPAR gamma and restoration of adriamycin-mediated inhibition of adipogenesis by PPAR gamma over-expression. Toxicol Mech Methods. 2012;22(7):540-546.DOI: 10.3109/15376516.2012.692110.

Molehin OR, Adeyanju AA, Adefegha SA, Oyeyemi AO, Idowu KA. Protective mechanisms of protocatechuic acid against doxorubicin-induced nephrotoxicity in rat model. J Basic Clin Physiol Pharmacol. 2019;30(4):1-10.DOI: 10.1515/jbcpp-2018-0191.

Kassab RB, Theyab A, Al-Ghamdy AO, Algahtani M, Mufti AH, Alsharif KF, et al. Protocatechuic acid abrogates oxidative insults, inflammation, and apoptosis in liver and kidney associated with monosodium glutamate intoxication in rats. Environ Sci Pollut Res Int. 2022;29(8):12208-12221.DOI: 10.1007/s11356-021-16578-4.

Tanaka T, Tanaka T, Tanaka M. Potential cancer chemopreventive activity of protocatechuic acid. J Exp Clin Med. 2011;3(1):27-33.DOI: 10.1016/j.jecm.2010.12.005.

Lin HH, Chen JH, Chou FP, Wang CJ. Protocatechuic acid inhibits cancer cell metastasis involving the down‐regulation of Ras/Akt/NF‐κB pathway and MMP‐2 production by targeting RhoB activation. Br J Pharmacol. 2011;162(1):237-254.DOI: 10.1111/j.1476-5381.2010.01022.x.


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.